Evolving important role of lutetium-177 for therapeutic nuclear medicine

Current Radiopharmaceuticals

Volumn 8, Issue 2, 2015, Pages 78-85

  Pillai, Ambikalmajan M R ^a  

^a Molecular Group of Companies   (India)

^b Russ)   (United States)

Author keywords

Antibodies; Bone pain palliation; Isotope production; Lutetium 177; Peptides; Targeted radionuclide therapy; Therapeutic radiopharmaceuticals

Indexed keywords

LUTETIUM; LUTETIUM 177; RADIOPHARMACEUTICAL AGENT; RADIOISOTOPE;

ARTICLE; CLINICAL PRACTICE; FUTUROLOGY; HUMAN; LARGE SCALE PRODUCTION; MEDICAL SOCIETY; NUCLEAR MEDICINE; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION SAFETY; RADIOCHEMISTRY; RADIOISOTOPE THERAPY; TREATMENT OUTCOME; DRUG DESIGN; PROCEDURES;

DRUG DESIGN; HUMANS; LUTETIUM; NUCLEAR MEDICINE; RADIOISOTOPES;

EID: 84940910902     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471008666150312155959     Document Type: Article

References (54)

1. [1] Anderson, J.; Farmer, F.T.; Inst, P.; Haggith J.W.; Hill, M. The treatment of myelomatosis with lutecium-177. Br. J. Radiol., 1960, 374-378.
2. [2] Bard, D.R.; Knight, C.G.; Page-Thomas, D.P. Effect of the intraarticular injection of lutecium-177 in chelator liposomes on the progress of experimental arthritis rabbits. Clin. Exp. Rheumatol. 1985, 3, 237-42.
3. [3] Simon, J.; Wilson D.A.; Volkert, W.A.; Troutner, D.E.; Goeckeler, W.F. Organic amine phosphonic acid complexes for the treatment of calcific tumors. United States, 1990. The Dow Chemical Company (Midland, MI) 4898724. http://www.freepatentsonline.com/4898724.html.
4. [4] Keeling, A.A.; Vaughan, A.T.M. Factors influencing the adsorption of Lutetium-177 on hydroxyapatite. Nucl. Med. Biol.,1988, 15, 489-492.
5. [5] Schlom, J.; Siler, K.; Milenic, D.E.; Eggensperger, D.; Colcher, D.; Miller, L.S.; Houchens, D., Goeckeler, W. Monoclonal antibodybased therapy of a human tumor xenograft with a 177Lutetiumlabeled immunoconjugate. Cancer Res., 1991, 51, 2889-2896.
6. [6] Balasubramanian, P.S. Separation of carrier-free lutetium-177 from neutron irradiated natural ytterbium target. J.Radioanal. Nucl. Chem., 1994, 185, 305-310.
7. [7] Ando, A.; Ando, I.; Tonami, N.; Kinuya, S.; Kazuma, K.; Kataiwa, A.; Nakagawa, M.; Fujita, N. 177Lu-EDTMP: A potential therapeutic bone agent. Nucl. Med. Commun., 1998, 19, 587-591.
8. [8] Zaknun, J.J.; Bodei, L.; Mueller-Brand, J.; Pavel, M.E.; Baum, R.P.; Horsch, D.; O’Dorisio, T.M.; Howe, J.R.; Cremonesi, M; Kwekkeboom, D.J. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging, 2013, 40, 800-816.
9. [9] Breeman, W.A.; de Jong, M.; Kwekkeboom, D.J.; Valkema, R.; Bakker, W.H.; Kooij, P.P.; Visser, T.J.; and Krenning, E.P. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur. J. Nucl. Med., 2001, 28, 1421-9.
10. [10] Bodei, L.; Cremonesi M.; Rocca P.; Bartolomei, M.; Chinol M. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur. J. Nucl. Med., 2001, 31: 1038-46.
11. [11] Bushnell D, Menda Y, O'Dorisio T, Madsen M, Miller S, Carlisle T, Squires S, Kahn D, Walkner W, Connolly M, O'Dorisio S, Karwal M, Ponto J, Bouterfa H. Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487) (OctreoTher) treatment. Cancer Biother Radiopharm, 2004, 19, 35-41
12. [12] Pillai, M.R.A; Chakraborty, S.; Das, T.; Venkatesh, M.; Ramamoorthy, N. Production logistics of 177Lu for radionuclide therapy. Appl. Radiat. Isot., 2003, 59, 109-118
13. [13] Kwekkeboom, D.J.; Bakker, W.H.; Kooij, P.P.M. [177Lu-DOTA0,Tyr3]octreotate: Comparison with [111In-DTPA0]octreotide in patients. Eur. J. Nucl. Med., 2001, 28, 1319-1325.
14. [14] Delpassand, E.S.; Samarghandi, A.; Zamanian, S.; Wolin, E.M.; Hamiditabar, M.; Espenan, G.D.; Erion, J.L; O'Dorisio, T.M.; Kvols, L.K.; Simon J, Wolfangel, R.; Camp, A.; Krenning, E.P.; Mojtahedi, A. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas, 2014, 43, 518-25.
15. [15] Pillai, M.R.A.; Venkatesh, M.; Banerjee, S.; Samuel, G.; Kothari, K.; Dash, A.; Unni, P.R.; Korde, A.; Bapat K, Pandey, U.; Das T.; Chakraborty S.; Mukherjee, A.; Sarma H.D. Development of radioactively labelled cancer seeking biomolecules for targeted therapy, In IAEA TECDOC 1359: Labelling techniques of biomolecules for targeted radiotherapy, 2002, 107-122. http://wwwpub.iaea.org/MTCD/publications/PDF/te_1359_web.pdf
16. [16] Preparation and quality control of 177Lu-DOTATATE for targeted therapy. In IAEA Technical Report Series 458: Comparative Evaluation of Therapeutic Radiopharmaceuticals. IAEA, 2007, 17-23. http://www-pub.iaea.org/MTCD/publications/PubDetails.asp?pubId=7654
17. [17] Mathe, D.; Balogh, L.; Polyak, A.; Keraly, R.; Pawlak, D.; Zaknun, J.; Pillai, M.R.A.; Janoki, G.A. Multi-species animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP formulation. Nucl. Med. Biol., 2010, 37, 215-226.
18. [18] Yuan, J.; Liu, C.; Liu, X.; Wang, Y.; Kuai, D.; Zhang, G.; Zaknun, J.J. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study. Clin. Nucl. Med. 2013, 38, 88.
19. [19] Agarwal, K.K.; Singla, S.; Arora, G.; Bal, C.; 177Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study. Eur. J. Nucl. Med. Mol. Imaging, 2014, (E published)
20. [20] Kondev, F.G. 177Lu. In Be et al. (Eds.) Table of Radionuclides, Vol 2, A=151-242, Monographie BIPM-5, Sevres, pp.107-112.
21. [21] Kossert, K., Nahle, O.J.; Ott, O.; Dersch, R. Activity determination and nuclear decay data of 177Lu. Appl. Radiat. Isot., 2012, 70, 2215–2221.
22. [22] Banerjee, S.; Pillai, M.R.A.; Knapp, F.F.; Lutetium-177 Therapeutic Radiopharmaceuticals-Linking Chemistry, Radiochemistry and Practical Applications. Chem. Rev., 2015, 115, 2934-2974.
23. [23] Toporov, Y.G.; Tarasov, V.A.; Andreyev, O.I.; Zotov, E.A.; Gavrilov, V.D.; Kupriyanov, A.L.; Kuznetsov, R.A. In: Report on the 1st research coordination meeting on ‘Development of therapeutic radiopharmaceuticals based on 177Lu for radionuclide therapy’. Vienna, Austria: International Atomic Energy Agenc, 2006, 152-62.
24. [24] Hermanne, A.; Takacs, S.; Goldberg, M.B.; Lavie, E.; Shubin, Y.N; Kolovalev, S. Deutron-induced reactions on Yb: measured cross sections and rationale for production pathways of carrier-free, medically relevant radionuclides. Nucl.Instrum. Methods Phys. Res. B, 2006, 247, 223-231.
25. [25] Manenti, S.; Bonardi, M.L.; Gini, L.; Groppi, F. Physical optimization of production by deuteron irradiation of high specific activity (177g)Lu suitable for radioimmunotherapy. Nucl. Med. Biol., 2014, 41, 407-409.
26. [26] Mirzadeh, S.; Du, M.; Beets, A.L.; Knapp, F.F. Jr. Method for preparing high specific activity 177Lu. United States Patent 6716353, http://www.google.com/patents/US6716353, 2004.
27. [27] Dvorakova, Z. Production and chemical processing of 177Lu for nuclear medicine at the Munich research reactor FRM-II. Dissertation. http://mediatum.ub.tum.de/doc/625564/625564.pdf
28. [29] Roig, O.; Couture, A.; Neutron capture cross section on Lu isotopes at DANCE. In Proc. 10th Symposium on Nuclei in the Cosmos, Mackinac Island, Michigan, USA, 2008. http://pos.sissa.it/archive/conferences/053/077/NIC%20X_077.pdf. Accessed on 11th August 2014.
29. [30] International Atomic Energy Agency. Research Reactor data base. http://nucleus.iaea.org/RRDB/RR/ReactorSearch.aspx?rf=1
30. [31] Toporov, V.A.; Tarasov, V.A.; Andreyev, O.I.; Zotov, E.A.; Kupriyanov, N.; Gavrilov, V.D.; Semenov, A.L. Production of high specific activity 177Lu using the SM research reactor. In, Proceedings, 9th International Symposium on the Synthesis and Applications of Isotopes and Isotopically Labeled Compounds, Edinburgh, Scotland, 2006, Abstract # 0-51, p. 65.
31. [32] Knapp, F.F., Jr.; Mirzadeh, S.; Beets, A.L. Reactor production and processing of therapeutic radioisotopes for applications in nuclear medicine, J. Radioanal. Nucl. Chem. Lett., 1996, 205, 93-100.
32. [33] Knapp, F.F. Jr.; Mirzadeh, S.; Beets, A.L.; Du, M. Production of therapeutic radioisotopes in the ORNL High Flux Isotope Reactor for applications in nuclear medicine, oncology and interventional cardiology, J. Radioanal. Nucl. Chem.2005, 263, 503-509.
33. [34] Ponsard, B. Production of radioisotopes in the BR2 high-flux reactor for applications in nuclear medicine and industry. J. Label. Compds. Radiopharm,. 2007, 50 333-337.
34. [35] Ketring, A.R.; Erhardt, G.; Embree, M. F., et al., Production and supply of high specific activity radioisotopes for radiotherapy applications. J. ALASBIMN, 2003, 5, 19.
35. [36] Mikolajczak, R.; Parus, J.L.; Pawlak, D.; Zakrzewska, E.; Michalak, W.; Sasinowska, I. Reactor-produced 177Lu of specific activity and purity suitable for medical applications. J. Radioanal. Nucl. Chem., 2003, 25, 53-57.
36. [37] Dvorakova, Z.; Henkelmann, R.; Lin, X.; Tuerler, A.; Gerstenberg, H. Production of 177Lu at the new research reactor FRM-II: Irradiation yield of 176Lu (n,')177Lu, Appl. Radiat. Isot. 2008, 66, 147-151.
37. [38] Chakraborty, S.; Vimalnath, K.V.; Lohar, S.P.; Shetty, P.; Dash, A.; On the practical aspects of large-scale production of 177Lu for peptide receptor radionuclide therapy using direct neutron activation of 176Lu in a medium flux research reactor: the Indian experience. Radioanal. Nucl. Chem. 2014, 302, 233-243.
38. [39] Knapp, F.F. Jr.; Mirzadeh, S., Beets, A. L.; Garland, M. Reactor production of high specific activity lutetium-177, Eur. J. Nucl. Med., 2005, 31 (Suppl. 2) (2005) S387.
39. [40] Mirzadeh, S.; Mausner, L.F.; Garland, M. Reactor-Produced Medical Radioisotopes, in “Handbook of Nuclear Chemistry”, Vol. 4, Chapter 3, pp. 1-46, A. Vertes, N.S. Klencsar, Eds; Kluwer Academic Publishers, Amsterdam, 2003.
40. [41] Mikolajczak, R.; Pawlak, D.; Zuchlinska, M.; Parus, J.L. Separation of carrier-free 177Lu from ytterbium. Transactions of the American Nuclear Society. TANSAO, 2008, 98, 908.
41. [42] Chakravarty, R.; Das, T.; Dash, A.; Venkatesh, M. An electroamalgamation approach to isolate no carrier added 177Lu from neutron irradiated Yb for biomedical applications. Nucl. Med. Biol., 2010, 37, 811-820.
42. [43] So, L.V.; Morcos, N.; Zaw, M., Pelligrni, P.; Greguric, I. Alternative chromatographic processes for no-carrier added 177Lu radioisotope production – Part I. multi column chromatographic process for clinical applicability. J. Radioanal. Nucl. Chem., 2008, 277, 663-674.
43. [44] So, L.V.; Morcos, N.; Zaw, M.; Pelligrni, P.; Greguric, I.; Nevissi, A. Alternative chromatographic processes for no-carrier-added 177Lu radioisotope production – Part II. The conventional column chromatographic separation combined with HPLC for higher purity. J. Radioanal. Nucl. Chem., 2008, 277, 675-683.
44. [45] Liu, S.; Edwards, D.S. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconj. Chem., 2011, 12, 7-34.
45. [46] Nuclide Safety Data Sheet-Lutetium-177. http://hpschapters.org/northcarolina/NSDS/177LuPDF.pdf. Accessed on 1th August 2014.
46. [47] Piotr, G.; Pawlak, D.; Licinska, I.; Kaminska A. Evaluation of a freeze-dried kit for EDTMP-based bone-seeking radiopharmaceuticals. Appl. Radiat. Isot., 2003, 58, 481-488.
47. [48] Meredith, R.F.; Alvarez, R.D.; Partridge, E.E. Intraperitonealradioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother.Radiopharm.2001, 16, 305-315.
48. [49] Bander, N.H.; Milowsky, M.I.; Nanus, D.M.; Kostakoglu, L.; Vallabhajosula, S.; Goldsmith, S.J. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J. Clin. Oncl., 2005, 23, 4591-601.
49. [50] Forrer, F.; Oeschslin-Oberholzer C.; Campana B.; Herrmann R.; Maecke H.R.; Mueller-Brand J.; Lohri A. Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas. J. Nucl. Med., 2013, 54, 1045-52.
50. [51] Banerjee, S.; Das, T.; Chakraborty S.; Samuel G.; Korde, A.; Srivastava, S.; Venkatesh, M.; Pillai M.R.A. 177Lu-DOTA-Lanreotide: A novel tracer as a targeted agent for tumor therapy. Nucl. Med. Biol., 2004, 31, 753-759.
51. [52] Fani, M.; Maecke, H.R.; Okravi, S.M.; Radiolabelled peptides: valuable tools for detection and treatment of cancer. Theranostics., 2012, 2, 481-501.
52. [53] Zimmerman, R. Why are investors not interested in my radiotracer? The industrial and regulatory constraints in the development of radiopharmaceuticals. Nucl. Med. Biol., 2013, 40, 155-166.
53. [54] Chakravarty, R.; Dash, A; Pillai, M.R.A. Availability of yttrium-90: A nuclear medicine perspective. Cancer Biother and Radiopharm., 2012, 27, 621-641.
54. [55] Das, T.; Pillai, M.R.A. Options to meet the future global demand of radionuclides for radionuclide therapy. Nucl. Med. Biol., 2013, 40, 23-32.